AI Insight
A study by the Barcelona Institute for Global Health found that women who were inadvertently exposed to ivermectin during early pregnancy (from two weeks before conception through the first four weeks of pregnancy) did not show an increased risk of miscarriage, stillbirth, or major congenital anomalies. The research provides evidence regarding the safety profile of this antiparasitic medication during very early pregnancy stages. However, the researchers emphasize that the sample size remains limited and current medical recommendations should not be changed based on these findings alone.
Why it matters
This research addresses an important safety question for women in regions where ivermectin is used for parasitic infections, as inadvertent exposure during early pregnancy can occur before women realize they are pregnant. The findings provide reassurance about early exposure while appropriately noting the need for more data before modifying clinical guidelines.
Understand the Science
A study led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by the “la Caixa” Foundation, found no increased risk of miscarriage, stillbirth or major congenital anomalies among women inadvertently exposed to ivermectin from two weeks before conception through the first four weeks of pregnancy. The findings, published in eClinicalMedicine, add to the available evidence on the safety of this antiparasitic drug during the very early stages of pregnancy, although the researchers stress that the number of cases remains too small to warrant changes to current recommendations.